title: Significant Treatment Effect of Bupropion in Patients With Bipolar Disorder but Similar Phase-Shifting Rate as Other Antidepressants: A Meta-Analysis Following the PRISMA Guidelines.
abstract: Bupropion is widely used for treating bipolar disorder (BD), and especially those with depressive mood, based on its good treatment effect, safety profile, and lower risk of phase shifting. However, increasing evidence indicates that the safety of bupropion in BD patients may not be as good as previously thought. The aim of this study was to summarize data on the treatment effect and safety profile of bupropion in the treatment of BD via a meta-analysis. Electronic search through PubMed and ClinicalTrials.gov was performed. The inclusion criteria were: (i) studies comparing changes in disease severity before and after bupropion treatment or articles comparing the treatment effect of bupropion in BD patients with those receiving other standard treatments; (ii) articles on clinical trials in humans. The exclusion criteria were (i) case reports/series, and (ii) nonclinical trials. All effect sizes from 10 clinical trials were pooled using a random effects model. We examined the possible confounding variables using meta-regression and subgroup analysis. Bupropion significantly improved the severity of disease in BD patients (P < 0.001), and the treatment effect was similar to other antidepressants/standard treatments (P = 0.220). There were no significant differences in the dropout rate (P = 0.285) and rate of phase shifting (P = 0.952) between BD patients who received bupropion and those who received other antidepressants. We could not perform a detailed meta-analysis of every category of antidepressant, nor could we rule out the possible confounding effect of concurrent psychotropics or include all drug side effects. Furthermore, the number of studies recruited in the meta-analysis was relatively small. Our findings reconfirm the benefits of bupropion for the treatment of bipolar depression, which are similar to those of other antidepressants. However, the rate of phase shifting with bupropion usage was not as low compared to other antidepressants as previously thought, which should serve to remind clinicians of the risk of phase shifting when prescribing bupropion to BD patients regardless of the suggestions of current clinical practice guidelines.
authors.affiliation: From the Kaohsiung Municipal Kai-Syuan Psychiatric Hospital (D-JL), Kaohsiung; Department of Psychiatry (P-TT, C-KW), Tsyr-Huey Mental Hospital, Kaohsiung Jen-Ai's Home; Department of Neurology (Y-WC), E-Da Hospital; Department of Psychiatry (P-YL), Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine; and Institute for Translational Research in Biomedical Sciences (P-YL), Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
authors.forename: Dian-Jeng
authors.initials: DJ
authors.lastname: Li
authors.forename: Ping-Tao
authors.initials: PT
authors.lastname: Tseng
authors.forename: Yen-Wen
authors.initials: YW
authors.lastname: Chen
authors.forename: Ching-Kuan
authors.initials: CK
authors.lastname: Wu
authors.forename: Pao-Yen
authors.initials: PY
authors.lastname: Lin
mesh_terms: D000928:Antidepressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000188:drug therapy*; D016642:Bupropion / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D012720:Severity of Illness Index
chemical_list: D000928:Antidepressive Agents; D016642:Bupropion